Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Hologic (HOLX)
NASDAQ:HOLX
Earnings Data
Report Date
Apr 30, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
1.02Last Year’s EPS
1.03Same Quarter Last Year
Based on 16 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 05, 2025
|% Change Since: -11.65%
|Next Earnings Date:Apr 30, 2025
Earnings Call Sentiment|Neutral
Hologic's earnings call presented a mixed outlook. The company showed strength in its Diagnostics division and maintained strong operating margins, but faced challenges in Breast Health and Skeletal businesses, along with lowered revenue guidance. The commitment to maintaining EPS guidance despite revenue challenges highlights operational efficiency.Company Guidance
During the call, Hologic provided guidance for their fiscal year 2025, projecting total revenue between $4.05 billion and $4.10 billion, reflecting a $100 million reduction from previous estimates, primarily due to currency headwinds and softer Breast Health capital sales. Despite these revenue adjustments, they maintained their non-GAAP EPS guidance of $4.25 to $4.35, showcasing their operational efficiency. The first quarter saw a 1% revenue increase to $1.022 billion on a constant currency basis, with non-GAAP EPS reaching $1.03, a 5% year-over-year growth. Key metrics included a non-GAAP gross margin of 61.6%, a 90 basis point increase in operating margins, and a net margin of 23.4%. They also highlighted strong performance in the Diagnostics division, with 9.1% organic growth excluding COVID-19 sales, and outlined expectations for gradual revenue growth improvement throughout the year, ending with strong growth in Q4.Diagnostics Revenue Growth
The Diagnostics division reported revenue of $470.6 million, showing a 5.2% growth and a 9.1% organic growth excluding COVID-related sales. Molecular diagnostics grew by 6.7% or 11% when excluding COVID-related sales.
Non-GAAP EPS Performance
Non-GAAP earnings per share were $1.03, at the high end of the guidance range and an increase of 5% year-over-year.
Strong Operating Margin
Non-GAAP operating margins improved by 90 basis points, demonstrating substantial operating leverage.
Gynesonics Acquisition
Hologic completed the acquisition of Gynesonics, which had about $28 million in revenue in its most recent fiscal year and is expected to grow at a healthy double-digit rate.
---
HOLX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
HOLX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 05, 2025 | $72.80 | $65.45 | -10.10% |
| Nov 04, 2024 | $83.72 | $78.80 | -5.88% |
| Jul 29, 2024 | $79.64 | $82.51 | +3.60% |
| May 02, 2024 | $75.91 | $76.54 | +0.83% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Hologic (HOLX) report earnings?
Hologic (HOLX) is schdueled to report earning on Apr 30, 2025, TBA Not Confirmed.
What is Hologic (HOLX) earnings time?
Hologic (HOLX) earnings time is at Apr 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is HOLX EPS forecast?
HOLX EPS forecast for the fiscal quarter 2025 (Q2) is 1.02.
---
